Research
Hormonal
Reduction in chin subcutaneous adipose tissue (chin-SAT) is independently associated with improvements in glycemic control (fasting glucose, HbA1c, HOMA-IR) and lipid profiles, even after adjusting for changes in visceral adipose tissue (VAT) and waist circumference.
Losing chin fat may be a sign of improving metabolic health, specifically insulin sensitivity. While you cannot spot-reduce, the reduction of this specific fat depot correlates with better blood sugar control, independent of how much belly fat you lose.
GoodSupportsHIGH confidence
After adjustment to VAT, waist-circumference, or weight-changes, chin-SAT 18-month reduction was associated with favorable changes in fasting-glucose (β = 0.10; p = 0.05), HbA1c (β = 0.12; p = 0.03), and homeostasis-model-assessment-of-insulin-resistance (β = 0.12; p = 0.03).
Why this rating
RCT design with multivariate adjustment for VAT and waist circumference strengthens the causal inference for this specific depot.
Source
The Effect of Weight-Loss Interventions on Cervical and Chin Subcutaneous Fat Depots; the CENTRAL Randomized Controlled Trial
Gal Tsaban et al. · Nutrients · 2021
DOI 10.3390/nu13113827
rct · n=278Cited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term weight loss via lifestyle interventions reduces cervical subcutaneous adipose tissue (cervical-SAT) significantly, whereas chin subcutaneous adipose tissue (chin-SAT) shows a significant initial reduction but rebounds to baseline levels after 18 months.Good
- Reduction in cervical subcutaneous adipose tissue (cervical-SAT) is independently associated with improvements in lipid profiles (triglycerides, LDL-C, cholesterol/HDL ratio) and leptin levels, independent of visceral adipose tissue (VAT).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →